Sol-Gel Technologies Ltd. (SLGL)
| Market Cap | 223.80M |
| Revenue (ttm) | 8.77M |
| Net Income (ttm) | -29.29M |
| Shares Out | 23.00M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $10.21 |
| Previous Close | $9.94 |
| Change ($) | 0.27 |
| Change (%) | 2.69% |
| Day's Open | 10.00 |
| Day's Range | 10.00 - 10.44 |
| Day's Volume | 11,833 |
| 52-Week Range | 7.00 - 16.69 |
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 63.27% and -59.15%, respectively, for the quarter ended March 2021.
- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ®
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
NEW YORK, April 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised ...
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...
NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and ...
SolGel Technologies Ltd. (SLGL) was a big mover last session on higher-than-average trading volume.
SolGel Technologies Ltd. (SLGL) witnessed a jump in share price last session on above-average trading volume.
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 12.20% and -725.03%, respectively, for the quarter ended December 2020.
• Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively
NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing brande...
NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing brande...
- PDUFA Goal Date Set for August 1, 2021
Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug.
Shares of Sol-Gel Technologies (NASDAQ:SLGL) moved higher by 0.1% after the company reported Q3 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.37), which beat the es...
NESS ZIONA, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...
NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing brande...
- PDUFA Goal Date Set for April 26, 2021
NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing bra...
NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded an...
NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and...
NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing an...
NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and...
Generic Product Collaborations between the Companies Now Cover Ten Products Generic Product Collaborations between the Companies Now Cover Ten Products
NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing an...
NESS ZIONA, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and ...
Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share
NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing an...
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea
Sol-Gel Technologies: A Promising Small-Cap Dermatology Player In 2020
NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing and...
The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.
Sol-Gel Shines In Treating 2 Skin Disorders, NDAs Expected For Both Indications In 2020
NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topic...
The small-cap company announced promising results from a clinical trial.
Sol Gel Technologies (SLGL) news for Monday concerning an acne drug study with incredibly positive results has SLGL stock taking off. The post Sol Gel Technologies News: SLGL Stock Skyrockets 80% on Acn...
Shares of the Israel-based, clinical-stage dermatology company Sol Gel Technologies Ltd (NASDAQ: SLGL) were more than doubling Monday.
Shares of Sol-Gel Technologies Ltd. SLGL, -5.82% gained 154% in premarket trading on Monday after the Israeli drugmaker said its acne drug Twyneo met the primary endpoints in two late-stage trials.
NESS ZIONA, Israel, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an investigation...
NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in ...
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Sol-Gel Technologies Ltd. said Monday that two late-stage trials of a treatment for papulopustular rosacea produced positive results.
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
About SLGL
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, w... [Read more...]
| Industry Biotechnology | IPO Date Jan 23, 2018 |
| CEO Alon Seri-Levy | Employees 65 |
| Stock Exchange NASDAQ | Ticker Symbol SLGL |
Financial Performance
In 2020, SLGL's revenue was $8.77 million, a decrease of -61.71% compared to the previous year's $22.90 million. Losses were -$29.29 million, 19.0% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 95.94% from the latest price.